Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes

John F. Seymour; Pierre Fenaux; Lewis R. Silverman; Ghulam J. Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Alan F. List; Steven D. Gore; Jay Backstrom; David McKenzie; C. L. Beach

doi:10.1016/j.critrevonc.2010.04.005

Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes

John F. Seymour, Pierre Fenaux, Lewis R. Silverman, Ghulam J. Mufti, Eva Hellstrom-Lindberg, Valeria Santini, Alan F. List, Steven D. Gore, Jay Backstrom, David McKenzie, C. L. Beach

Research output: Contribution to journal › Literature review › peer-review

111 Citations (Scopus)

Abstract

This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (>= 75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial. Patients were randomized to AZA (75 mg/m(2)/day subcutaneously x 7 days every 28 days) (n = 38) or CCR (n = 49) and had median ages of 78 and 77 years, respectively. AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0.26, 0.89]; p = 0.0193) and 2-year OS rates were 55% vs 15% (p= 75 years with good performance status and higher-risk MDS. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Original language	English
Pages (from-to)	218 - 227
Number of pages	10
Journal	Critical Reviews in Oncology/Hematology
Volume	76
Issue number	3
DOIs	https://doi.org/10.1016/j.critrevonc.2010.04.005
Publication status	Published - Dec 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.critrevonc.2010.04.005

Cite this

Seymour, J. F., Fenaux, P., Silverman, L. R., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., List, A. F., Gore, S. D., Backstrom, J., McKenzie, D., & Beach, C. L. (2010). Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 76(3), 218 - 227. https://doi.org/10.1016/j.critrevonc.2010.04.005

@article{045d35f59d5a426caa96a41e853e97fe,

title = "Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes",

abstract = "This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (>= 75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial. Patients were randomized to AZA (75 mg/m(2)/day subcutaneously x 7 days every 28 days) (n = 38) or CCR (n = 49) and had median ages of 78 and 77 years, respectively. AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0.26, 0.89]; p = 0.0193) and 2-year OS rates were 55% vs 15% (p= 75 years with good performance status and higher-risk MDS. (C) 2010 Elsevier Ireland Ltd. All rights reserved.",

author = "Seymour, {John F.} and Pierre Fenaux and Silverman, {Lewis R.} and Mufti, {Ghulam J.} and Eva Hellstrom-Lindberg and Valeria Santini and List, {Alan F.} and Gore, {Steven D.} and Jay Backstrom and David McKenzie and Beach, {C. L.}",

year = "2010",

month = dec,

doi = "10.1016/j.critrevonc.2010.04.005",

language = "English",

volume = "76",

pages = "218 -- 227",

journal = "Critical Reviews in Oncology/Hematology",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

Seymour, JF, Fenaux, P, Silverman, LR, Mufti, GJ, Hellstrom-Lindberg, E, Santini, V, List, AF, Gore, SD, Backstrom, J, McKenzie, D & Beach, CL 2010, 'Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes', Critical Reviews in Oncology/Hematology, vol. 76, no. 3, pp. 218 - 227. https://doi.org/10.1016/j.critrevonc.2010.04.005

TY - JOUR

T1 - Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes

AU - Seymour, John F.

AU - Fenaux, Pierre

AU - Silverman, Lewis R.

AU - Mufti, Ghulam J.

AU - Hellstrom-Lindberg, Eva

AU - Santini, Valeria

AU - List, Alan F.

AU - Gore, Steven D.

AU - Backstrom, Jay

AU - McKenzie, David

AU - Beach, C. L.

PY - 2010/12

Y1 - 2010/12

N2 - This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (>= 75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial. Patients were randomized to AZA (75 mg/m(2)/day subcutaneously x 7 days every 28 days) (n = 38) or CCR (n = 49) and had median ages of 78 and 77 years, respectively. AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0.26, 0.89]; p = 0.0193) and 2-year OS rates were 55% vs 15% (p= 75 years with good performance status and higher-risk MDS. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

AB - This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (>= 75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial. Patients were randomized to AZA (75 mg/m(2)/day subcutaneously x 7 days every 28 days) (n = 38) or CCR (n = 49) and had median ages of 78 and 77 years, respectively. AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0.26, 0.89]; p = 0.0193) and 2-year OS rates were 55% vs 15% (p= 75 years with good performance status and higher-risk MDS. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

U2 - 10.1016/j.critrevonc.2010.04.005

DO - 10.1016/j.critrevonc.2010.04.005

M3 - Literature review

VL - 76

SP - 218

EP - 227

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 3

ER -

Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this